Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

On the basis of strong preclinical rationale, we sought to confirm recommended phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor capivasertib and assess molecular markers of response and resistance. We performed a safety lead-in followed by expansion in endometrial...

Celý popis

Podrobná bibliografia

Vydané v:	Clinical cancer research Ročník 27; číslo 23; s. 6354
Hlavní autori:	Westin, Shannon N, Labrie, Marilyne, Litton, Jennifer K, Blucher, Aurora, Fang, Yong, Vellano, Christopher P, Marszalek, Joseph R, Feng, Ningping, Ma, XiaoYan, Creason, Allison, Fellman, Bryan, Yuan, Ying, Lee, Sanghoon, Kim, Tae-Beom, Liu, Jinsong, Chelariu-Raicu, Anca, Chen, Tsun Hsuan, Kabil, Nashwa, Soliman, Pamela T, Frumovitz, Michael, Schmeler, Katheleen M, Jazaeri, Amir, Lu, Karen H, Murthy, Rashmi, Meyer, Larissa A, Sun, Charlotte C, Sood, Anil K, Coleman, Robert L, Mills, Gordon B
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.12.2021
Predmet:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Female Humans Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Phthalazines Piperazines Pyrimidines Pyrroles Triple Negative Breast Neoplasms - drug therapy
ISSN:	1557-3265, 1557-3265
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!